Interplay between CD44 expression and acidic mucin histochemical alterations in colorectal cancer

Document Type : Original Article

Authors

Pathology department, Faculty of medicine, Beni-Suef University, Beni-Suef, Egypt

Abstract

Colorectal cancer (CRC) represents a significant global health problem. Finding the biomarkers is crucial for the diagnosis and prognosis prediction. CD44 is a cancer stem cell (CSC) marker that plays an important role in tumor cell proliferation, adhesion, migration, and invasion. Altered mucin expression has been observed in cancer cells and also affects their biologic properties. This study aimed to analyze CD44 expression, assess acidic mucin histochemical alterations in CRC cases and to find the relation between both. A total of 40 colectomy specimens were included. Sections from formalin-fixed paraffin embedded blocks of the tumors were stained immunohistochemically with anti-CD44 antibodies and histochemically using Alcian Blue (AB) at pH 2.5. AB staining was positive in 26 (65%) cases including all mucinous carcinoma cases. It was significantly related to tumor histology (P= 0.000), lymph node status (P=0.000) and TNM staging groups (P= 0.000). CD44 expression was positive in 30 (75%) cases. Positive cases were scored as +1, +2 and +3. CD44 expression was significantly related to lymph node status (P= 0.001) and TNM staging groups (P= 0.006).  There was a significant relationship between CD44 expression and AB staining (P = 0.006) with a moderate negative correlation (r= -0.424). Increased CD44 expression and decreased acidic mucin correspond with lymph node metastasis and higher stage in CRC cases, suggesting both as indicators of worse prognosis. 

Keywords

Main Subjects

References

  1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019; 14:89-103.
  2. El-Moselhy EA, Hassan AM, El-Tiby DM, Abdel-Wahed A, Mohammed AS. Colorectal cancer in Egypt: clinical, life-style and socio-demographic risk factors. PRAS1. 2017; 4:1–15.  
  3. Bateman LB, Khamess S, Abdelmoneim SE, Arafat W, Fouad MN, Khamis Y, et al. Designing an Effective Colorectal Cancer Screening Program in Egypt: A Qualitative Study of Perceptions of Egyptian Primary Care Physicians and Specialists. Oncologist 2020; 25(10):e1525-e31.
  4. Choi JE, Bae JS, Kang MJ, Chung MJ, Jang KY, Park HS. et al., Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance. Oncol Rep. 2017; 38:1695-1705.
  5. Wan Q, Zhang D, Zhou Q, Li M, Wang Y, Song Y. et al., Association of CD44 gene rs187115 polymorphism with colorectal cancer risk and prognosis in Chinese Han population: a case-control study. Aging (Albany NY). 2019; 1:9616-9625.
  6. Iseki Y, Shibutani M, Maeda K, Nagahara H, Ikeya T, Hirakawa K. Significance of E-cadherin and CD44 expression in patients with unresectable metastatic colorectal cancer. Oncol Lett. 2017; 14:1025-1034.
  7. Mohamed SY, Kaf RM, Ahmed MM, Elwan A, Ashour HR, Ibrahim A. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma. J Gastrointest Cancer. 2019; 50:824-837.
  8. Kasprzak A, Seraszek-Jaros A, Jagielska J, Helak-Łapaj C, Siodła E, Szmeja J. et al., The Histochemical Alterations of Mucin in Colorectal Carcinoma Quantified by Two Efficient Algorithms of Digital Image Analysis. Int J Mol Sci. 2019; 20:4580.
  9. Milosevic V, Vukmirovic F, Zindovic M, Krstic M, Milenkovic S, Jancic S. Interplay between expression of leptin receptors and mucin histochemical aberrations in colorectal adenocarcinoma. Rom J Morphol Embryol. 2015; 56:709-716.
  10. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P. et al., WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76:182-188.
  11. Gonzalez RS, Raza A, Propst R, Adeyi O, Bateman J, Sopha SC. et al., Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book". Arch Pathol Lab Med. 2021; 145:607-626.
  12. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK. et al., AJCC Cancer Staging Manual. 8th ed. Springer International Publishing: American Joint Commission on Cancer. 2017.
  13. Lü X, Xu K, Lü H, Yin Y, Ma C, Liu Y. et al., CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas. Ultrastruct Pathol. 2011; 35:72-78.
  14. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC. et al., Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70:145-164.
  15. Jain P, Mondal SK, Sinha SK, Mukhopadhyay M, Chakraborty I. Diagnostic and prognostic significance of different mucin expression, preoperative CEA, and CA-125 in colorectal carcinoma: A clinicopathological study. J Nat Sci Biol Med. 2014; 5:404-408.
  16. Sakr SA, Abdel-Wahed MM, Abdou AG, El-Adely EK. Histochemical alterations in colorectal carcinoma and adenoma in Egyptian patients. Journal of Coastal Life Medicine.2016; 4: 14-20.
  17. Lin SJ, Arruda B, Burrough E. Alteration of Colonic Mucin Composition and Cytokine Expression in Acute Swine Dysentery. Vet Pathol. 2021; 58:531-541.
  18. Pothuraju R, Krishn SR, Gautam SK, Pai P, Ganguly K, Chaudhary S. et al., Mechanistic and Functional Shades of Mucins and Associated Glycans in Colon Cancer. Cancers (Basel). 2020; 12:649.
  19. Hadi N I, Abdul Shakoor K, Waseem B. Is mucin content a prognostic indicator in colorectal carcinoma? J. Surg. Pak. Int. 2009; 14:7-10.
  20. Danquah KO, Adjei E, Quayson S, Adankwah E, Gyamfi D, Ossei PPS. et al., Mucin expression patterns in histological grades of colonic cancers in Ghanaian population. Pan Afr Med J. 2017; 27:267.
  21. Lugli A, Zlobec I, Baker K, Minoo P, Tornillo L, Terracciano L. et al., Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status. J Clin Pathol. 2007; 60:534-539.
  22. Vincent A, Ouelkdite-Oumouchal A, Souidi M, Leclerc J, Neve B, Van Seuningen I. Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies. World J Stem Cells. 2019; 11:920-936.
  23. Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018; 11:64.
  24. Ngan CY, Yamamoto H, Seshimo I, Ezumi K, Terayama M, Hemmi H. et al., A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol. 2007; 95:652-662.
  25. Ismaiel NE, Sharaf WM, Helmy DO, Zaki MM, Badawi MA, Soliman AS. Detection of Cancer Stem Cells in Colorectal Cancer: Histopathological and Immunohistochemical Study. Open Access Maced J Med Sci. 2016; 4:543-547.
  26. Holah NS, Aiad HA, Asaad NY, Elkhouly EA, Lasheen AG.  Evaluation of the role of CD44 as a cancer stem cell marker in colorectal carcinoma: immunohistochemical study. Menoufia Medical Journal. 2017; 30:174–183.
  27. Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH. et al., Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 2009; 59:241-246.
  28. Chaitra LP, Prashant A, Gowthami CS, Hajira B, Suma MN, Mahesh SS. et al., Detection of cancer stem cell-related markers in different stages of colorectal carcinoma patients of Indian origin by immunohistochemistry. J Cancer Res Ther. 2019; 15:75-81.
  29. Wang Z, Tang Y, Xie L, Huang A, Xue C, Gu Z. et al., The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis. Front Oncol. 2019; 9:309.
  30. Rohani P, Noroozinia F, Modarresi P, Abbasi A. CD44 Standard Isoform; Not a Good Marker for Colon Cancer. Int J Cancer Manag. 2017; 10:e9166.

 

 

Files

Share

How to cite

Statistics